Covid, AstraZeneca: "Italy's goal is 5 million doses of vaccine by the end of March"
AstraZeneca-EU: there is a risk of half-delivery, but discussion is still ongoing
Share
01 March 2021 "The patent refers to research and the intellectual property of research, in the case of the AstraZeneca vaccine the intellectual property belongs to Oxford. What we are absolutely willing to do is to give up production licenses so that it can be accelerated. that we have done in recent months: the 20 production plants are by no means exclusively ours ".
So on Buongiorno, on Sky TG24, Lorenzo Wittum, CEO of AstraZeneca Italia.
"We are already doing it - he continued - and we are willing to increase it, but I want to be very clear: to increase it we need two conditions: a partner capable of managing this production process, because technology transfer is absolutely not easy, then we have I need a partner with a production capacity of tens of millions per month. It's not easy. I spent from June to December looking for partners, both in Italy and in Europe. Last week we announced an agreement with a German company to increase the production of active substance, which is where we had the problems with yield. "
Meanwhile, AstraZeneca is in contact with Aifa (Italian drug agency) for a possible authorization of the anti-Covid vaccine for the over 65. "It is a decision that Aifa must take with the Ministry of Health, but we have from Scotland additional data that may be useful. In France and Germany this hypothesis is already being evaluated, we will see in the coming days ".